2 Pharmaceutical Stocks to Buy at a Discount
If you see news about the pharmaceutical industry today and it isn't directly about GLP-1 weight loss drugs, it's likely to include at least a mention of this new class of medications. GLP-1 drugs are an exciting development, for sure. However, Wall Street has a bad habit of getting so myopically focused on one thing that stock prices become irrational.
This is why you might want to look at Bristol Myers Squibb (NYSE: BMY) and (NYSE: MRK) today. Here's a look at each one.
You need to have a reference point when you examine valuations. Right now, the best reference point is GLP-1 leader Eli Lilly (NYSE: LLY). There's no question the company is doing exceptionally well right now, having taken the pole position in a hot new drug niche with Mounjaro and Zepbound.
Source Fool.com
Merck KGaA Aktie
Leichtes Buy-Übergewicht bei der Merck KGaA Aktie mit 4 zu 0 Einschätzungen.
Das Community-Kursziel von 142 € für Merck KGaA deutet auf eine deutliche Steigerung um mehr als 20% gegenüber dem aktuellen Kurs von 118.0 € hin.
